Therapeutic Efficacy In Clinical Trials In the randomized, open-label, multinational, phase III SIMPLE-moderate trial ( NCT04292730 ), patients with moderate COVID-19 pneumonia receiving 5-day remdesivir treatment were significantly more likely to have clinical improvement at day 11 than those receiving standard of care (SOC) alone (odds ratio (OR) 1.65; 95% CI 1.09–2.48; p = 0.017); the difference between patients receiving 10-day remdesivir and those receiving SOC alone did not reach statistical significance (OR 1.31; 95% CI 0.88–1.95) [ 38 ].
1
—
—